WO2011092835A1 - 持続性口腔用殺菌消毒液 - Google Patents
持続性口腔用殺菌消毒液 Download PDFInfo
- Publication number
- WO2011092835A1 WO2011092835A1 PCT/JP2010/051203 JP2010051203W WO2011092835A1 WO 2011092835 A1 WO2011092835 A1 WO 2011092835A1 JP 2010051203 W JP2010051203 W JP 2010051203W WO 2011092835 A1 WO2011092835 A1 WO 2011092835A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ppm
- oral cavity
- ions
- bactericidal
- cavity according
- Prior art date
Links
- 230000002421 anti-septic effect Effects 0.000 title claims abstract description 25
- 238000004659 sterilization and disinfection Methods 0.000 title abstract description 34
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 91
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- 239000002562 thickening agent Substances 0.000 claims abstract description 18
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- 239000002211 L-ascorbic acid Substances 0.000 claims abstract description 11
- 235000000069 L-ascorbic acid Nutrition 0.000 claims abstract description 11
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 11
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 10
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 10
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 7
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 7
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000010199 sorbic acid Nutrition 0.000 claims abstract description 7
- 239000004334 sorbic acid Substances 0.000 claims abstract description 7
- 229940075582 sorbic acid Drugs 0.000 claims abstract description 7
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 3
- 210000000214 mouth Anatomy 0.000 claims description 73
- 239000000645 desinfectant Substances 0.000 claims description 63
- -1 iron ions Chemical class 0.000 claims description 29
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 19
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 12
- 235000005487 catechin Nutrition 0.000 claims description 12
- 229910052742 iron Inorganic materials 0.000 claims description 11
- 239000000341 volatile oil Substances 0.000 claims description 11
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 8
- 229920001817 Agar Polymers 0.000 claims description 8
- 239000008272 agar Substances 0.000 claims description 8
- 235000010419 agar Nutrition 0.000 claims description 8
- 229940050390 benzoate Drugs 0.000 claims description 8
- 150000001765 catechin Chemical class 0.000 claims description 8
- 239000012676 herbal extract Substances 0.000 claims description 8
- 235000010413 sodium alginate Nutrition 0.000 claims description 8
- 239000000661 sodium alginate Substances 0.000 claims description 8
- 229940005550 sodium alginate Drugs 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 7
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 7
- 229920002261 Corn starch Polymers 0.000 claims description 7
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 7
- 239000008120 corn starch Substances 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 claims description 6
- 241000272875 Ardeidae Species 0.000 claims description 6
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 6
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 claims description 6
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 6
- 229960004365 benzoic acid Drugs 0.000 claims description 6
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 claims description 6
- 229910001431 copper ion Inorganic materials 0.000 claims description 6
- 229910001453 nickel ion Inorganic materials 0.000 claims description 6
- 229910052709 silver Inorganic materials 0.000 claims description 6
- 239000004332 silver Substances 0.000 claims description 6
- 229940075554 sorbate Drugs 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- 235000013878 L-cysteine Nutrition 0.000 claims description 5
- 239000004201 L-cysteine Substances 0.000 claims description 5
- 229940037003 alum Drugs 0.000 claims description 5
- 229910001429 cobalt ion Inorganic materials 0.000 claims description 5
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- 239000008399 tap water Substances 0.000 claims description 5
- 235000020679 tap water Nutrition 0.000 claims description 5
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 4
- 241001131796 Botaurus stellaris Species 0.000 claims description 4
- 244000004281 Eucalyptus maculata Species 0.000 claims description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 229940023476 agar Drugs 0.000 claims description 4
- 229950001002 cianidanol Drugs 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 229940099112 cornstarch Drugs 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 3
- 235000013628 Lantana involucrata Nutrition 0.000 claims description 3
- 244000178870 Lavandula angustifolia Species 0.000 claims description 3
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 3
- 244000042664 Matricaria chamomilla Species 0.000 claims description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 3
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 claims description 3
- 244000179970 Monarda didyma Species 0.000 claims description 3
- 235000010672 Monarda didyma Nutrition 0.000 claims description 3
- 240000007673 Origanum vulgare Species 0.000 claims description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 3
- 241000018646 Pinus brutia Species 0.000 claims description 3
- 235000011613 Pinus brutia Nutrition 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 3
- 240000002657 Thymus vulgaris Species 0.000 claims description 3
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 3
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- 239000001102 lavandula vera Substances 0.000 claims description 3
- 235000018219 lavender Nutrition 0.000 claims description 3
- 239000010677 tea tree oil Substances 0.000 claims description 3
- 229940111630 tea tree oil Drugs 0.000 claims description 3
- 239000001585 thymus vulgaris Substances 0.000 claims description 3
- 229930007845 β-thujaplicin Natural products 0.000 claims description 3
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 2
- 229960001950 benzethonium chloride Drugs 0.000 claims description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims description 2
- HVHSWFRODXRTOQ-UHFFFAOYSA-N azanium;1,2-dimethyl-3-octadecylbenzene;chloride Chemical compound [NH4+].[Cl-].CCCCCCCCCCCCCCCCCCC1=CC=CC(C)=C1C HVHSWFRODXRTOQ-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 21
- 206010022000 influenza Diseases 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 7
- 206010057190 Respiratory tract infections Diseases 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 206010046306 Upper respiratory tract infection Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 206010048685 Oral infection Diseases 0.000 abstract description 4
- 208000020029 respiratory tract infectious disease Diseases 0.000 abstract description 4
- 150000002148 esters Chemical class 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 150000001559 benzoic acids Chemical class 0.000 abstract 1
- 201000009240 nasopharyngitis Diseases 0.000 abstract 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical class C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 61
- 241000894006 Bacteria Species 0.000 description 53
- 230000001954 sterilising effect Effects 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- 238000012360 testing method Methods 0.000 description 33
- 230000000694 effects Effects 0.000 description 29
- 210000004400 mucous membrane Anatomy 0.000 description 26
- 241000700605 Viruses Species 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 19
- 230000000249 desinfective effect Effects 0.000 description 18
- 239000007788 liquid Substances 0.000 description 13
- 244000052769 pathogen Species 0.000 description 12
- 210000003296 saliva Anatomy 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000003097 mucus Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 206010006326 Breath odour Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000002925 dental caries Diseases 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000004302 potassium sorbate Substances 0.000 description 4
- 235000010241 potassium sorbate Nutrition 0.000 description 4
- 229940069338 potassium sorbate Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 208000005888 Periodontal Pocket Diseases 0.000 description 3
- 201000005702 Pertussis Diseases 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004195 gingiva Anatomy 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000009965 odorless effect Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001333951 Escherichia coli O157 Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000032139 Halitosis Diseases 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940044631 ferric chloride hexahydrate Drugs 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 2
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 2
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- YVOOPGWEIRIUOX-BXRBKJIMSA-N (2r)-2-azanyl-3-sulfanyl-propanoic acid Chemical compound SC[C@H](N)C(O)=O.SC[C@H](N)C(O)=O YVOOPGWEIRIUOX-BXRBKJIMSA-N 0.000 description 1
- KWIPUXXIFQQMKN-UHFFFAOYSA-N 2-azaniumyl-3-(4-cyanophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC=C(C#N)C=C1 KWIPUXXIFQQMKN-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001660259 Cereus <cactus> Species 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 229910021503 Cobalt(II) hydroxide Inorganic materials 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000005955 Ferric phosphate Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 241000604961 Wolbachia Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 229940090948 ammonium benzoate Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229940049699 cobalt gluconate Drugs 0.000 description 1
- SCNCIXKLOBXDQB-UHFFFAOYSA-K cobalt(3+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Co+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SCNCIXKLOBXDQB-UHFFFAOYSA-K 0.000 description 1
- ASKVAEGIVYSGNY-UHFFFAOYSA-L cobalt(ii) hydroxide Chemical compound [OH-].[OH-].[Co+2] ASKVAEGIVYSGNY-UHFFFAOYSA-L 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 1
- QSYYPORYZDRMNA-UHFFFAOYSA-L copper;azane;dichloride Chemical compound N.N.[Cl-].[Cl-].[Cu+2] QSYYPORYZDRMNA-UHFFFAOYSA-L 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 229940032296 ferric chloride Drugs 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- VEPSWGHMGZQCIN-UHFFFAOYSA-H ferric oxalate Chemical compound [Fe+3].[Fe+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O VEPSWGHMGZQCIN-UHFFFAOYSA-H 0.000 description 1
- 229940032958 ferric phosphate Drugs 0.000 description 1
- 235000003132 food thickener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 description 1
- HVENHVMWDAPFTH-UHFFFAOYSA-N iron(3+) trinitrate hexahydrate Chemical compound O.O.O.O.O.O.[Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O HVENHVMWDAPFTH-UHFFFAOYSA-N 0.000 description 1
- SZQUEWJRBJDHSM-UHFFFAOYSA-N iron(3+);trinitrate;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O SZQUEWJRBJDHSM-UHFFFAOYSA-N 0.000 description 1
- 229910000399 iron(III) phosphate Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- KBJMLQFLOWQJNF-UHFFFAOYSA-N nickel(ii) nitrate Chemical compound [Ni+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O KBJMLQFLOWQJNF-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000000090 ruminant stomach Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 description 1
- 229940019931 silver phosphate Drugs 0.000 description 1
- 229910000161 silver phosphate Inorganic materials 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- OXAGUGIXGVHDGD-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate;dihydrate Chemical compound O.O.[Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OXAGUGIXGVHDGD-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- JDLYKQWJXAQNNS-UHFFFAOYSA-L zinc;dibenzoate Chemical compound [Zn+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 JDLYKQWJXAQNNS-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Definitions
- the present invention can be used for the prevention of oral infections including upper respiratory tract infections and dental fields, the reduction of inflammation, and as a support for treatment, and is particularly effective for the prevention of influenza and colds. Involved in persistent bactericidal disinfectants.
- One of them is a symbiotic relationship
- ruminant stomach and cellulolytic bacteria, legumes and rhizobia are known as typical examples.
- Recent examples include Wolbachia as a source of vitamin B group, and the establishment of infection through collaboration between bacteria and influenza virus has also attracted attention as a kind of symbiotic relationship. This discovery was triggered by a group of dental departments who participated in oral care with the aim of preventing aspiration pneumonia caused by oral disease in elderly care recipients.
- Non-Patent Document 1 Non-Patent Document 1
- gargle the effect of “gargle”. Whatever the reason is gargle (1) If it is just gargle, it will settle in the oral cavity and throat, and the number of inhabiting bacteria will be slightly reduced, and will be restored soon. (2) If the virus adsorbs to the throat epithelial cell (mucosa), it will enter the cell in 10 to 15 minutes. In other words, if you don't gargle all the time, you can't prevent infection. This is unrealistic. (3) Even if gargle is frequently performed, frequent gargles mechanically damage mucosal epithelial cells, which is equivalent to the action of protease. (4) It also wipes away mucus, the key defense function, to facilitate infection with pathogens.
- Universal disinfectant is a basic substance of life, its main ingredient is “amino acids, vitamins, and minerals” as its main component, and it is extremely safe and contains general bacteria, acid-fast bacteria, fungi, spores and It has a wide antibacterial spectrum up to viruses, and it is a disinfectant that is wide and convenient for disinfection, including skin, mucous membranes, wounds, excrement, instruments, equipment, environment, and even plants. Table 1 below outlines the results of the disinfection effect of the universal disinfectant and a known disinfectant.
- Example 4 of Patent Document 1 when a universal sterilizing solution is used as gargle water, it has an equivalent disinfecting effect as compared to the conventional poppyyon iodine, and the gargle effect lasts for 60 minutes. It has been confirmed that it is superior in terms of safety and safety.
- the present invention eliminates the drawbacks of the conventional gargles described above and further reaches the upper respiratory tract infections, oral infections and dental infections including the block of influenza infection system based on the new theory. Effective for the prevention and treatment of inflammation, relief of inflammation and removal of bad breath, and can be used safely for multiple purposes. It has excellent disinfection effect and has excellent disinfection effect.
- the object is to provide a liquid.
- the present inventors have improved the disinfection effect against viruses and bacteria than the universal disinfection solution by mixing a thickener and an astringent with the universal disinfection solution described in Patent Document 1.
- the present invention has been completed by successfully increasing the sustainability of the disinfection effect.
- an antibacterial disinfecting solution for oral cavity comprising a metal ion having antibacterial action, L-cysteine, L-ascorbic acid, a non-ionic surfactant, a thickener and an astringent
- Antibacterial metal ions are trivalent iron ions (Fe 3+ ), divalent iron ions (Fe 2+ ), zinc ions (Zn 2+ ), copper ions (Cu 2+ ), cobalt ions (1), or two or more selected from the group consisting of (Co 2+ ), nickel ions (Ni 2+ ) and silver ions (Ag + );
- the concentration of antibacterial metal ions is 50 to 200 ppm for III-valent iron ions, 110 to 400 ppm for II-valent iron ions, 7.5 to 125 ppm for zinc ions, 15 to 60 ppm for copper ions, cobalt
- Bactericidal disinfectant for oral cavity [6] The bactericidal antiseptic solution for oral cavity according to any one of the above [1] to [5], wherein the concentration of the surfactant excluding nonionic is 20 to 100 ppm, [7] The oral cavity according to any one of [1] to [6], wherein the thickener is one or more selected from the group consisting of corn starch, agar, sodium alginate, chondroitin sulfate and hyaluronic acid.
- Disinfectant When the thickener is added alone, it is 20000-35000 ppm for corn starch, 1000-1500 ppm for agar, 5000-8000 ppm for sodium alginate, 8000-15000 ppm for chondroitin sulfate, and 3000-5000 ppm for hyaluronic acid.
- the bactericidal disinfectant for oral cavity according to the above [7], [9] The bactericidal antiseptic solution for oral cavity according to any one of the above [1] to [8], wherein the astringent is alum, catechin, bittern or hop extract, [10]
- Bactericidal disinfectant for oral cavity [12] The bactericidal antiseptic solution for oral cavity according to the above [11], wherein the concentration of sorbic acid, sorbate, benzoic acid, benzoate and paraoxin benzoate is 50 to 100 ppm, [13] Any one of [1] to [12], further including one or more selected from the group consisting of 5 to 10 ppm of sialic acid, 10 to 20 ppm of protein, and 100 to 200 ppm of herbal extract or essential oil Bactericidal disinfectant for oral cavity, [14] One or more herbs extract or essential oil selected from the group consisting of eucalyptus, mint, chamomile, lavender, oregano, glove, rosemary, thyme, neroli, pine, bergamot, cedarwood, hinokitiol, and tea tree oil The bactericidal disinfectant for oral cavity according to the above [13], [15] The bactericidal antiseptic solution for oral cavity according to any one of
- the bactericidal disinfectant for oral cavity of the present invention is excellent in safety, excellent in bactericidal disinfection against viruses and bacteria, and excellent in sustainability of the effect. It is possible to prevent various diseases that develop due to oral or upper respiratory tract infection for a long time. Therefore, it is possible to efficiently prevent infection of the disease by gargle and rinsing mouth regularly about 3-4 times a day. In addition, by enabling sterilization of causative bacteria of caries existing in the oral cavity, oral care such as prevention of dental caries and bad breath can be achieved.
- Patent Document 1 As described above, the present invention was developed based on Patent Document 1, and all the following components described in Patent Document 1 can be incorporated into the present invention.
- the metal ion having antibacterial action may be any metal ion used in Patent Document 1, for example, III-valent iron ion (Fe 3+ ), II-valent iron.
- III-valent iron ion (Fe 3+ ), II-valent iron examples include ions (Fe 2+ ), zinc ions (Zn 2+ ), copper ions (Cu 2+ ), cobalt ions (Co 2+ ), nickel ions (Ni 2+ ), and silver ions (Ag + ). These metal ions may be used alone or in combination.
- the amount of the metal ion in the bactericidal antiseptic solution for oral cavity of the present invention may be appropriately adjusted so as to obtain a desired sterilizing power.
- iron ion is 50 to 200 ppm
- II-valent iron ion is 110.
- L-Cysteine L-cysteine is a kind of sulfur-containing amino acid and is an essential component for skin metabolism, assists the production of collagen and cooperates with L-ascorbic acid to suppress the generation of melanin. It is a major component of skin, nails and hair and is widely distributed throughout the body. Surprisingly, depending on how L-cysteine itself is used, it not only exhibits antibacterial action, but also has an SH group (thiol group in which sulfur and hydrogen are bonded) and antibacterial metal ions in the molecular structure. Amplifies strong bactericidal properties, promotes the destruction of cells by inhibiting DNA, inactivating enzymes, inhibiting metabolic functions, denaturing proteins or generating free radicals.
- the optimum concentration differs slightly depending on the type and concentration of metal ions contained, but is preferably several times the ion concentration.
- the content of L-cysteine in the sterilizing / disinfecting solution of the present invention is preferably 100 to 1000 ppm.
- L-ascorbic acid The action of L-ascorbic acid is as described above.
- the content of L-ascorbic acid in the bactericidal antiseptic solution for oral cavity of the present invention is preferably 100 to 500 ppm.
- the surfactant used in Patent Document 1 may be used.
- examples include ionic surfactants and amphoteric surfactants.
- AES alkylbenzene sulfonate
- AS alcohol sulfate
- AS alcohol sulfate
- Cationic surfactant Stearyldimethylbenzylammonium chloride, benzalkonium chloride, benzethonium chloride (amphoteric surfactant) Alkyldiaminoethylglycine hydrochloride, alkylpolyaminoethylglycine hydrochloride
- the surfactants other than the nonionic system may be used alone or
- the bactericidal action is amplified and the bactericidal time is remarkably shortened by containing 20 to 100 ppm of the surfactant excluding the nonionic type.
- the bactericidal disinfectant for oral cavity of the present invention contains at least one selected from the group consisting of sorbic acid, sorbate, benzoic acid, benzoate, and paraoxybenzoate esters, so that it can be sterilized. It becomes possible to improve power.
- the sorbate include potassium sorbate and sodium sorbate.
- the benzoate include potassium benzoate, sodium benzoate, calcium benzoate, ammonium benzoate, and zinc benzoate.
- Examples of the paraoxybenzoates include isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, ethyl paraoxybenzoate, butyl paraoxybenzoate, and propyl paraoxybenzoate.
- the concentration of the sorbic acid, potassium sorbate, benzoic acid, benzoate, and paraoxybenzoic acid esters in the bactericidal antiseptic solution for oral cavity is preferably 50 to 100 ppm.
- a Solution I 0.96 g of ferric chloride hexahydrate (FeCl 3 .6H 2 O) is dissolved in 200 ml of purified water.
- Solution II 1 g of L-cysteine, 0.1 g of L-ascorbic acid, 0.05 g of potassium sorbate, and 0.1 g of sodium lauryl sulfate are dissolved in 800 ml of purified water.
- Solution I and Solution II were mixed and 0.6 ml of 1N hydrochloric acid was added to adjust to pH 3.0 to produce a universal sterilizing solution.
- the “universal sterilization liquid” is composed of safe components and has a wide antibacterial spectrum. Therefore, the following examination was carried out for the purpose of maintaining the antiseptic effect while maintaining this antibacterial spectrum.
- the present inventors have inferred that the outflow of this mucus can be partially solved by giving viscosity to the gargle without replacing the mucus. This is because it is assumed that by replacing mucus, which is originally present, by covering the mucous membrane with the mucous membrane, it is possible to capture viruses and bacteria, which are external enemies, with mucus while maintaining the effect of conventional gargle. .
- An Ostwald relative viscometer was used for viscosity measurement.
- the principle is to measure the relative viscosity by measuring the time during which the liquid surface that sucks up the sample liquid under a constant temperature passes through the score lines L1 to L2 by its own weight.
- the viscosity of the “universal sterilization liquid” was 1 as equal to tap water.
- the viscosity was adjusted by adding a food thickener (starch, dietary fiber, etc.) to the universal sterilizing solution.
- S. aureus 209P as a representative of Gram-negative (-) bacteria.
- E. coli O-157 was adopted.
- Each bacterial suspension (1 ⁇ 10 9 cells / saline water) was dropped into the viscous test disinfectants a1, b1, and c1 so as to be 1% by weight, and one platinum ear-fishing fungus over time. Then, it was inoculated into ordinary broth and agitated and cultured at 37 ° C. under aerobic condition. And the grade of the bactericidal disinfection effect was determined by the presence or absence of the proliferation of bacteria. The results are shown in Table 4 below.
- the sterilizing power of universal sterilizing liquids A, B, and C prepared with purified water is expressed as “++” for convenience. ++: There is no significant difference between the sterilizing power of the universal sterilizing solution and the test sterilizing solution. ++: The sterilizing power of the test disinfecting solution decreases and sterilization takes time. ++: The sterilizing power of the test disinfecting solution. Fell considerably. Cannot be used-: Test bactericidal solution is inactivated
- thickeners other than those listed above were tested, and corn starch, agar, sodium alginate, chondroitin sulfate, hyaluronic acid are suitable as thickeners for all-purpose disinfectants and used in combination. It proved that there was no problem.
- Astringent action means that a protein in the vicinity of the surface of the mucous membrane or skin is temporarily or continuously reversibly coagulated and denatured to produce a water-insoluble substance.
- a dense barrier on the surface of the mucous membrane or skin, the effect of alleviating external irritation and improving antiseptic, analgesic, texture, etc. is shown.
- the throat is covered with a pleated mucous membrane and is strongly converging.
- Examples of foods and food additives having an astringent action include alum, catechin (tannin), bittern, hop extract and the like.
- Test disinfectants a2, b2, and c2 obtained by adding various concentrations of astringents to the all-purpose disinfectant disinfectants A, B, and C have a concentration that does not cause discomfort or discomfort in the oral cavity or throat by 20 people. It was monitored and the bactericidal power when the upper limit concentration was added was verified in the same manner as in Table 4.
- Table 7 shows the results of the test disinfectant a2, but the test disinfectants b2 and c2 also showed similar results.
- the change of the bacteria was measured according to the usual method by wiping with a sterile gauze while changing the location of the upper gingival part with the passage of time.
- catechins were almost aseptic until about 90 minutes, and the appearance of bacteria was gradually recognized thereafter, but after 180 minutes, the number of bacteria was 10-15% before gargle.
- the mechanism by which the sterilization effect by gargle continues is that the mucous membrane shrinks due to the astringent action, and the antiseptic solution is embraced and covered with an insoluble thin film, resulting in a double strong barrier on the mucosa, such as viruses and bacteria It is inferred that pathogens block the adhesion to mucous membranes and skin surfaces.
- astringent when used alone, it is superior in bactericidal power and its sustainability, and the optimum concentration is 8000 to 12000 ppm for alums, and 5000 to 5000 for catechins. It was confirmed that it was 10,000 ppm, bitterns 8000-20000 ppm, and hop extract 10,000-15000 ppm.
- bitterns are bitter liquids remaining after the salt extracted by boiling seawater, and the main components thereof include magnesium sulfate, and magnesium chloride, sodium chloride, potassium chloride and the like. Although it is generally used for coagulation of tofu, it has been elucidated that it has a fat absorption inhibitory action and a blood sugar inhibitory action, and is now applied to various foods and cosmetics. Meanwhile, catechins have been confirmed to have various pharmacological effects such as antibacterial activity, antiviral activity, antioxidant activity, anticancer activity, and detoxification activity.
- Table 8 shows a part of the results for the bactericidal disinfectant E for oral cavity obtained by adding various effective thickeners and astringents to the universal disinfectant disinfectant E.
- the thickener used in the bactericidal antiseptic solution for oral cavity of the present invention is one or more selected from the group consisting of corn starch, agar, sodium alginate, chondroitin sulfate and hyaluronic acid. It is preferable. In addition, when added alone as a thickener concentration, it should be 20000-35000 ppm for corn starch, 1000-1500 ppm for agar, 5000-8000 ppm for sodium alginate, 8000-15000 ppm for chondroitin sulfate, and 3000-5000 ppm for hyaluronic acid. Is preferred.
- the astringent used in the bactericidal disinfectant for oral cavity of the present invention is preferably one selected from the group consisting of alums, catechins, bitterns and hop extracts.
- the concentration of the astringent is preferably 8000 to 12000 ppm for alums, 5000 to 10,000 ppm for catechins, 8000 to 20000 ppm for bitterns, and 10,000 to 15000 ppm for hop extract.
- bactericidal antiseptic solution for oral cavity Improvement of affinity for mucous membrane
- the main components of bactericidal disinfecting solution for oral cavity are amino acids, vitamins and minerals that are basic components of living body.
- certain herbal extracts and essential oils are effective.
- the herb extract or essential oil may be one or more selected from the group consisting of eucalyptus, mint, chamomile, lavender, oregano, glove, rosemary, thyme, neroli, pine, bergamot, cedarwood, hinokitiol and tea tree oil. Can be mentioned.
- the inclusion of the herb extract or essential oil in the bactericidal antiseptic solution for oral cavity has the advantage of not only improving affinity to the mucous membrane but also having antibacterial activity and exhibiting excellent anti-inflammatory properties. Furthermore, the fragrance of herbal extracts and essential oils reaches the limbic system directly through the mucous membranes, which is transmitted to the hypothalamus to stimulate the autonomic nervous system and hormone system, and the neurochemical substances involved in each are secreted. It is also expected to stimulate the immune system by adjusting the balance between the mind and body. Also, it has been scientifically confirmed that inhaled lungs are diffused and sent to capillaries throughout the body to produce a unique medicinal effect.
- Influenza is infected because hemagglutinin (HA), which is like a number of spines on the surface of the virus, adsorbs to sialic acid present in epithelial cells of the mucosa. Begins. Therefore, by containing a small amount of sialic acid (5-10ppm) in the bactericidal antiseptic solution for oral cavity, even if a large amount of virus enters the respiratory tract, it is first adsorbed on this sialic acid, and the viscous bactericidal disinfecting for oral cavity There is an advantage that the virus is entangled in the liquid and deactivated in a few minutes. Even if time elapses after gargle and the efficacy of gargle water drops, it is not easy to reach mucosal cells if the virus adsorbs to the sialic acid contained.
- HA hemagglutinin
- the bactericidal disinfectant for oral cavity of the present invention can be prepared by adding and mixing the above various components to water or heated water.
- the order of addition is not particularly limited.
- water used as a medium also includes tap water, ion exchange water, pure water, purified water, etc., and may be appropriately selected according to the purpose of use.
- the bactericidal disinfecting solution for oral cavity of the present invention by adjusting the acidity, it contributes to the maintenance and stability of the components of the disinfecting disinfecting solution and at the same time supports the penetration into the pathogen.
- the pH of the sterilizing / disinfecting solution of the present invention is preferably 2.5 to 4.0.
- a known pH adjuster can be used for adjusting the pH.
- the sterilization mentioned in the present invention refers to killing bacteria present in the oral cavity. Moreover, it can be said that the disinfection and sterilization in the present invention have a remarkable effect that is different from conventional products in that the effect is sustained.
- gargle is performed using a conventional gargle, the number of bacteria in the oral cavity is recovered over time even if it is once reduced.
- recovery of the number of bacteria in the oral cavity after gargle can be significantly delayed.
- the pathogen referred to in the present invention refers to viruses and bacteria that can cause disease by infection from the oral or upper respiratory tract, and is a causative agent of various infectious diseases such as intestinal infections and respiratory infections, Salmonella ( Salmonella spp.), Shigella spp., Vibrio parahaemolyticus, Vibrio choreae, Escherichia coli O-157, Campylobacter jejuni, pseudomembranous colitis (Clostridium difficile), Clostridium perfringens, Yersinia enterocolitica, Helicobacter pylori, Ameba Shigella (Entemoeba histolytica), Bacillusu cereus, Staphylococcus scus Clostridium botulinum, Haemophilus influenzae, Streptococcus pneumoniae, Chlamiadia pneumoniae, Legionella lung Bacteria (Legionella pneumoniae), Branhamella catarrhalis, Mycobacterium tuberculosis
- viruses in the present invention include influenza virus, rhinovirus, coronavirus, adenovirus, RS virus, avian influenza virus, norovirus, hepatitis virus, AIDS virus, rotavirus and the like.
- the present invention it is possible to prevent infection of the pathogen from the oral or respiratory tract by sterilizing the mucous membrane such as the oral cavity and throat with the bactericidal disinfectant for oral cavity of the present invention by gargle, rinsing, etc. become.
- the bactericidal disinfectant for oral cavity of the present invention is composed of components with little irritation, and can be used for disinfection in the nasal cavity, which is another infection route.
- it is possible to prevent infection of the pathogen by including the oral sterilization liquid of the present invention in the oral cavity or by sterilizing the nasal cavity.
- the oral cavity and nasal cavity As a method for disinfecting the oral cavity and nasal cavity, conventional methods may be used.For example, in addition to gargle and rinsing, the oral cavity is sprayed with an oral bactericidal disinfectant or a swab containing an oral bactericidal disinfectant. Or what is necessary is just to contact the surface of a nasal cavity.
- non-human animals include domestic animals such as cats, dogs, rabbits, chickens, sheep, goats, pigs, cows and horses.
- the dose of oral bactericidal disinfectant appropriate for ensuring the preventive pharmaceutical benefit is selected according to parameters known to those skilled in the art, such as the age, sex, and weight of a human or non-human animal.
- the bactericidal antiseptic solution for oral cavity of the present invention is composed of components having excellent safety, and in addition to excellent bactericidal disinfection, viscosity and astringency are combined to prevent infection. It is presumed that an insoluble barrier is placed on the target mucosa or skin surface and a viscous bactericidal antiseptic solution is contained on the mucosa or skin surface to prevent infection by pathogens such as viruses and bacteria.
- the gargle water of the present invention can be produced in various ways by combining the constituents of the present invention and the concentration thereof, but here, it is limited to a representative example and adopted in the examples described later.
- the basic production method is preferably a method in which a solution [ ⁇ ] containing metal ions and [ ⁇ ] containing components other than metal ions are separately produced and mixed together (solution [ ⁇ ] + It is preferable that the thickener contained in the solution [ ⁇ ] is dissolved in advance by heating alone and the other components are added and dissolved in the solution.
- the respective volumes of the solution [ ⁇ ] and the solution [ ⁇ ] may be equal, but preferably about 1: 9 or 2: 8 can prevent the problem of precipitation of components.
- Dilute hydrochloric acid is preferable for adjusting the pH (2.5 to 4.0).
- ⁇ Solution ⁇ > and ⁇ Solution ⁇ > were mixed and prepared by adding 0.6 ml of 1N hydrochloric acid. Thereafter, the bactericidal disinfectant for oral cavity of the present invention (abbreviated as “gargle water”) of the present invention was produced in the same manner, and production examples 2 to 8 are summarized in Tables 9-1 and 9-2.
- this gargle water when used, bacteria are not detected until 15 minutes later, appear for the first time after 30 minutes, 3-5% even after 1 o'clock, and maintain the same level for a while, gradually after 6 hours It started to increase, and after 8 hours, it was around 20% (same level as 1 to 1.5 hours of universal sterilization solution), and it took 12 hours or more to recover to the original number of bacteria. Although the number of bacteria in saliva is different from the number of bacteria on the mucous membrane, it can be said that the effect of the present gargle can be maintained for at least 8 hours. Therefore, using this gargle water, for example, gargle three times a day in the morning, noon, and evening, it is extremely effective in preventing infection against pathogens that cause infection from the oral and upper respiratory tract. Is estimated to be obtained.
- Example 4 10 people who were bothered by bad breath were gargleed with gargle water produced by various production methods, 20 seconds 3 times (1 minute in total) twice / day for 1 week. The meal was free to eat except for odorous foods (garlic, garlic, etc.). Breathe into the smell bag (2L) made of polyester material with high odorlessness every morning when you get up (before brushing your teeth), seal it with a silicone jar, and increase and decrease the bad breath and perform a sensory test on the properties with three odor-sensitive monitors It was. A part of the results are shown in Table 13. In addition, the intensity of the odor sensation is displayed by a 6-step method. 0 ... Odorless 1 ... Slightly odor is finally felt 2 ... Smell that can be easily felt (the nature of odor can be imagined) 3 ... Clearly odor 4 ... Strong odor 5 ... Unusable odor
- ⁇ Test Example 5> Eight cases of periodontal disease that are difficult to treat (both have deep periodontal pockets) are treated with gargle water produced in Production Example 3 twice a day for only 2 months in the oral cavity for 2 months Continued. In all cases, Poryphyromonas gingivalis, Prevotella intermedia, and Actinobacillus actinomycetemcomitans, which have high periodontal pathogenicity, were present, and the gingiva was swollen to some extent, and halitosis was strong and tooth wobble was observed. The treatment results of three representative examples are shown in Table 14.
- gargle water of the present invention is an improvement in convenience that eliminates these drawbacks, and its use will be unlimited unless the infectious disease is extinct from the earth. For example, even in Japan, a country with advanced public health, 10 million people are infected with flu every year, and in 2009, a new swine-derived flu is rampant, especially among young people.
- gargle with this gargle water is simple and easy to defend and contain pandemic (global epidemic: estimated 100 million dead) due to mutation of highly pathogenic avian influenza virus (H1N5 type), which is also said to be a problem of time.
- pandemic global epidemic: estimated 100 million dead
- pandemic highly pathogenic avian influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
この発見のきっかけは高齢の要介護者を対象に口腔内疾患による誤嚥性肺炎の予防を目的に某歯科大の研究グループが口腔ケアに参加、専門の歯科衛生士による積極的な指導を1回/週、半年間実施したところ、日常生活の中で最も頻度の高い疾患である上気道感染症(90%は風邪症候群)のうち、その施設ではインフルエンザの発症率が従来の1/10に激減した。その理由を分析した結果、口腔内に存在するプロテアーゼ(蛋白分解酵素)活性の強い常在菌(一例:ブドウ球菌)や外来の菌が上気道の粘膜を覆う蛋白の膜を破壊することによってウイルスのレセプター(受容体:シアル酸)が露出、ウイルス表面に棘のようにあるHA(ヘマグリチオン)という糖蛋白がそれに吸着、融合して細胞内に浸入するという感染メカニズムを丁寧な歯磨きによる除菌が妨害しているものと推論した(非特許文献1)。この細菌学の新説は理論的整合性が高く、今後上記事例について幅広い年齢層を対象に大規模な臨床検証を進める必要があろうが昔から風邪の予防に推奨される「うがい」は歯磨きと同様、喉の粘膜に張り付いた細菌とウイルス並びに細菌の繁殖の温床たる口中の栄養分を洗い流すため、理に適った方法の一つであることは間違いなかろう。うがい液が単なる水より消毒効果があればなお一層望ましいことは言うまでもない。
何故かなればインフルエンザウイルスの遺伝子変異はそれが季節性、新型を問わず殊の外早くヒトの2000万倍とも言われワクチンの効果を否定するものではないが、その製造には毎年の流行の型の予測を含めて紆余曲折がしばしばで、その点、消毒液による予防措置は容易かつ簡単明瞭で広範囲に有効性を発揮し得る。
(1)単なるうがい程度では口腔内やのどに定着、生息している菌が多少減少するにしてその場限りでほどなく復元する。
(2)ウイルスはのどの上皮細胞(粘膜)に吸着したならば10分~15分で細胞内に侵入する。つまり四六時中うがいをしなければ感染を防ぎ切れない。これは非現実的である。
(3)仮に頻繁にうがいを行ったとしても度々のうがいは粘膜の上皮細胞を機械的に荒らしてしまいそれはプロテアーゼの作用に等しい。
(4)また防衛機能の要の粘液をも同時に拭い去り、病原体の感染を容易にする。
(5)従来から消毒用うがい液の副作用の問題がある。例えば汎用されるヨード系のうがい液は優れたものではあるが粘膜の細胞の障害性が認められ体質によってはアレルギー反応を起す。また甲状腺に疾患のある人には禁忌である。歯や衣服に着色性があり味覚の点でも不快に感じる人は少なくない。市販される他のうがい液についても程度の差はあれ副作用の問題が指摘されている。
(1) マウスに於けるLD50は経口投与(p.o)1mL 推定10mL・・・人に換算18L
(2) 腹腔投与(i.p):4mL・・・人に換算7.2L
(3) 動物細胞(サル腎CV-1及び人リンパ球)は10倍希釈で約半数の細胞は何ら障害を受けず増殖する
(4) 長期にわたり皮膚に塗布しても何ら異常は認められない
上記試験成績から「万能殺菌消毒液」の安全性は普通の飲用水やミネラル水に等しいと言っても過言ではない。
[1]抗菌作用を有する金属イオン、L-システイン、L-アスコルビン酸、非イオン系を除く界面活性剤、増粘剤及び収斂剤を含有することを特徴とする口腔用殺菌消毒液、
[2]抗菌作用を有する金属イオンがIII価の鉄イオン(Fe3+)、II価の鉄イオン(Fe2+)、亜鉛イオン(Zn2+)、銅イオン(Cu2+)、コバルトイオン(Co2+)、ニッケルイオン(Ni2+)及び銀イオン(Ag+)からなる群より選ばれる1種又は2種以上である前記[1]に記載の口腔用殺菌消毒液、
[3]抗菌作用を有する金属イオンの濃度が、III価の鉄イオンでは50~200ppm、II価の鉄イオンでは110~400ppm、亜鉛イオンでは7.5~125ppm、銅イオンでは15~60ppm、コバルトイオンでは180~300ppm、ニッケルイオンでは85~175ppm、及び銀イオンでは1~3ppmである前記[2]に記載の口腔用殺菌消毒液、
[4]L-システインの濃度が100~1000ppm及びL-アスコルビン酸の濃度が100~500ppmである前記[1]~[3]のいずれかに記載の口腔用殺菌消毒液、
[5]非イオン系を除く界面活性剤が、アルキルベンゼンスルホン酸塩、直鎖アルキルベンゼンスルホン酸塩、ポリオキシエチレンアルキルエーテル硫酸塩、高級アルコール硫酸エステル塩、ラウリル硫酸ナトリウム、ラウロイルサルコシンナトリウム、塩化ステアリルジメチルベンゼンアンモニウム、塩化ベンザルコニウム、塩化ベンゼントニウム、塩化アルキルジアミノエチルグリシン及び塩酸アルキルポリアミノエチルグリシンからなる群より選ばれる1種又は2種以上である前記[1]~[4]のいずれかに記載の口腔用殺菌消毒液、
[6]非イオン系を除く界面活性剤の濃度が20~100ppmである前記[1]~[5]のいずれかに記載の口腔用殺菌消毒液、
[7]増粘剤がコーンスターチ、寒天、アルギン酸ナトリウム、コンドロイチン硫酸塩及びヒアルロン酸からなる群より選ばれる1種又は2種以上である前記[1]~[6]のいずれかに記載の口腔用殺菌消毒液、
[8]増粘剤の濃度が単独添加の場合にはコーンスターチでは20000~35000ppm、寒天では1000~1500ppm、アルギン酸ナトリウムでは5000~8000ppm、コンドロイチン硫酸塩では8000~15000ppm、ヒアルロン酸では3000~5000ppmである前記[7]に記載の口腔用殺菌消毒液、
[9]収斂剤がミョウバン類、カテキン類、にがり類又はホップエキスである前記[1]~[8]のいずれかに記載の口腔用殺菌消毒液、
[10]収斂剤の濃度がミョウバン類では8000~12000ppm、カテキン類では5000~10000ppm、にがり類では8000~20000ppm、ホップエキスでは10000~15000ppmである前記[9]に記載の口腔用殺菌消毒液、
[11]ソルビン酸、ソルビン酸塩、安息香酸、安息香酸塩並びにパラオキシ安息香酸エステルからなる群より選ばれる1種又は2種以上をさらに含む前記[1]~[10]のいずれかに記載の口腔用殺菌消毒液、
[12]ソルビン酸、ソルビン酸塩、安息香酸、安息香酸塩及びパラオキシン安息香酸エステルの濃度が50~100ppmである前記[11]に記載の口腔用殺菌消毒液、
[13]シアル酸5~10ppm、プロテイン10~20ppm、及びハーブエキス又は精油100~200ppmからなる群より選ばれる1種又は2種以上をさらに含む前記[1]~[12]のいずれかに記載の口腔用殺菌消毒液、
[14]ハーブエキス又は精油がユーカリ、ミント、カモミール、ラベンダー、オレガノ、グローブ、ローズマリー、タイム、ネロリ、パイン、ベルガモット、シダーウッド、ヒノキチオール、及びティートリーオイルからなる群より選ばれる1種又は2種以上である前記[13]記載の口腔用殺菌消毒液、
[15]pHが2.5乃至4.0の範囲内に調整された前記[1]~[14]のいずれかに記載の口腔用殺菌消毒液、
[16]オストワルド相対粘度計による測定で、水道水の粘度を1とした場合の相対粘度が1.5~2.2である前記[1]~[15]のいずれかに記載の口腔用殺菌消毒液
に関する。
また、口腔内に存在する虫歯の原因菌などの殺菌を可能にすることで、虫歯防止、口臭防止など口腔ケアも可能となる。
抗菌作用を有する金属イオンとしては、前記特許文献1で使用される金属イオンであればよく、例えば、III価の鉄イオン(Fe3+)、II価の鉄イオン(Fe2+)、亜鉛イオン(Zn2+)、銅イオン(Cu2+)、コバルトイオン(Co2+)、ニッケルイオン(Ni2+)又は銀イオン(Ag+)が挙げられる。これらの金属イオンは単独でも併用してもよい。
本発明の口腔用殺菌消毒液中の前記金属イオンの量としては、所望の殺菌力が得られるように適宜調整すればよいが、例えば、鉄イオンでは50~200ppm、II価の鉄イオンでは110~400ppm、亜鉛イオンでは7.5~125ppm、銅イオンでは15~60ppm、コバルトイオンでは180~300ppm、ニッケルイオンでは85~175ppm及び銀イオンでは1~3ppmであることが好ましい。
L-システインは含硫アミノ酸の一種で皮膚の代謝に不可欠な成分でコラーゲンの生成を助けL-アスコルビン酸と協働してメラニンの発生を抑制する。皮膚、爪、髪の主要構成成分で体内に広く分布している。そして意外にもL-システインそのものも用い方次第で抗菌作用を発現するのみならず、分子構造中にSH基(硫黄と水素の結合したチオール基)と抗菌性の金属イオンとが結合、活性を増幅して強い殺菌性を発現、DNA阻害、酵素の失活、代謝機能の阻害、蛋白の変性またフリーラジカルの発生により菌体破壊を促進せしめる。強い抗酸化作用と還元作用で構成成分の安定性に寄与し、生体親和性が高く病原体に強く付着してひいては浸透性を助長しうる役割を担う。その至適濃度は含有する金属イオンの種類とその濃度により若干異なるが、イオン濃度の数倍程度が好ましい。例えば、本発明の殺菌消毒液中におけるL-システインの含有量は、100~1000ppmが好ましい。
L-アスコルビン酸の作用については前記の通りである。本発明の口腔用殺菌消毒液中におけるL-アスコルビン酸の含有量は、100~500ppmであることが好ましい。
非イオン系を除く界面活性剤としては、前記特許文献1で使用される界面活性剤であればよく、例えば、以下の陰イオン系界面活性剤、陽イオン系界面活性剤、両性界面活性剤が挙げられる。
(陰イオン系界面活性剤)
アルキルベンゼンスルホン酸塩(ABS系)、直鎖アルキルベンゼンスルホン酸塩(LAS系)、ポリオキシエチレンアルキルエーテル硫酸塩(AES系)、ラウリル硫酸ナトリウム、ラウロイルサルコシンナトリウム、高級アルコール硫酸エステル塩(AS)
(陽イオン系界面活性剤)
塩化ステアリルジメチルベンジルアンモニウム、塩化ベンザルコニウム、塩化ベンゼントニウム
(両性界面活性剤)
塩酸アルキルジアミノエチルグリシン、塩酸アルキルポリアミノエチルグリシン
前記非イオン系を除く界面活性剤は、1種又は2種以上を組み合わせて用いてもよい。
本発明の口腔用殺菌消毒液は、ソルビン酸、ソルビン酸塩、安息香酸、安息香酸塩、及びパラオキシ安息香酸エステル類からなる群より選ばれる1種以上を含有することで、殺菌力を向上することが可能になる。
前記ソルビン酸塩としては、ソルビン酸カリウム、ソルビン酸ナトリウムが挙げられる。
また、安息香酸塩としては、安息香酸カリウム、安息香酸ナトリウム、安息香酸カルシウム、安息香酸アンモニウム、安息香酸亜鉛が挙げられる。
また、パラオキシ安息香酸エステル類としては、パラオキシ安息香酸イソブチル、パラオキシ安息香酸イソプロピル、パラオキシ安息香酸エチル、パラオキシ安息香酸ブチル、パラオキシ安息香酸プロピルが挙げられる。
前記ソルビン酸、ソルビン酸カリウム、安息香酸、安息香酸塩、及びパラオキシ安息香酸エステル類の口腔用殺菌消毒液中の濃度は、50~100ppmが好ましい。
製造例A
溶液I:塩化第二鉄・六水和物(FeCl3・6H2O) 0.96gを精製水200mlに溶解する。
溶液II:L-システイン1g、L-アスコルビン酸0.1g、ソルビン酸カリウム0.05g、ラウリル硫酸ナトリウム0.1gを精製水800mlに溶解する。
次に溶液Iと溶液IIとを混和せしめ1規定の塩酸0.6mlを添加してpH3.0に調整して万能殺菌消毒液を製造した。
従来のうがいでは細菌、ウイルスや塵埃だけでなく、外敵からの防衛機能の要である粘膜付着の粘液をも洗い流し、粘膜があらわになってしまい、うがいをすることで返って感染のチャンスを与えているのではとの指摘がされていた。例えばカエルの体表面の粘液を洗剤などで綺麗に取り去ればたちまちツボカビ類に感染し程なく衰弱死することが知られているがこれに似た現象が従来のうがいでも生じている疑いがある。
実験に先立ち、どの程度の粘性までなら違和感や抵抗感がなくうがいをなし得るかを老若男女20人にモニターを依頼した。
+++ : 万能殺菌消毒液と試験消毒液との殺菌力との間に有為の差はない
++ : 試験消毒液の殺菌力が下落し、殺菌には時間を要する
+ : 試験消毒液の殺菌力がかなり下落。使用不可
- : 試験消毒液の殺菌力が失活
前記万能殺菌消毒液Aに寒天を0.15%含有する、相対粘度2.2を示す試験消毒液で1回15秒3回うがいを行い唾液による流出が比較的少ない上の歯肉部から15分毎に白金耳で釣菌するという簡易な細菌検査をした所、30分程度はほぼ無菌状態でその後は菌が徐々に増加していく様子が観察された。すなわち粘性を有する本液は僅かずつ粘膜から遊離していくものの1時間程度は殺菌能力を充分維持している状態で歯肉に付着していることを物語っていた。
実験の結果、上記粘性を示す各種増粘剤の濃度の範囲は以下の表5の通りである。
収斂作用とは、粘膜や皮膚の表面付近の蛋白質を一時的又は継続して可逆的に凝固、変性せしめることで、水不溶性物が生じ、その水不溶性物が被膜となって粘膜や皮膚の表面に緻密なバリアを張ることで、外部からの刺激を緩和し、防腐、鎮痛、食感等を向上する作用効果を示す。殊に喉はひだ状の粘膜に覆われて収斂作用を強く受ける。
次に該試験消毒液a2でうがいを行った場合、粘膜上に於ける殺菌持続時間を計測することにした。青色2号を0.05%量添加して上部の歯肉部で観察した所、収斂剤の種類により多少異なるがミョーバンでは約1.5時間、カテキンでは約2時間、にがりとホップエキスでは1時間強程度有効であった。結果を表7に示す。
以上の試験成績を踏まえて粘性と収斂性とを付与した場合の効果を検証してみることにした。
表8の結果は、万能殺菌消毒液Eをベースにした時の成績であるが万能殺菌消毒液A~Dをベースにした時も類似の好成績が得られた。
(I)粘膜親和性の向上
口腔用殺菌消毒液の主成分は生体の基本構成成分たるアミノ酸、ビタミン、ミネラルであり、元来生体や粘膜に対して親和性を有しているがより高い親和性を付与せしめることを鋭意追及した結果、或る種のハーブのエキスや精油が有効であることを突き止めた。
前記ハーブエキス又は精油としては、ユーカリ、ミント、カモミール、ラベンダー、オレガノ、グローブ、ローズマリー、タイム、ネロリ、パイン、ベルガモット、シダーウッド、ヒノキチオール及びティートリーオイルからなる群れより選ばれる1種又は2種以上が挙げられる。
尚、ハーブの香りそのものは、うがい後の約30分程で口中から自然消失する。
(イ)インフルエンザはウイルスの表面に幾つもの棘のようにある赤血球凝集素(HA)が粘膜の上皮細胞に存在するシアル酸に吸着することから感染が始まる。従って、口腔用殺菌消毒液の中に微量のシアル酸(5~10ppm)を含有せしめることによりウイルスが気道に多量に侵入して来てもこのシアル酸に先ず吸着し、粘性の口腔用殺菌消毒液にからみ取られウイルスは数分で失活してしまうという利点がある。仮にうがい後時間が経過してうがい水の効力が落ちたとしても含まれるシアル酸にウイルスが吸着したならば粘膜細胞までたどり着くのは容易ではない。
口腔内の或る種の細菌が産生する活性の強いプロテアーゼが喉の上皮細胞を荒らすことでウイルスの感染が容易となる。この作用の妨害にプロテインを口腔用殺菌消毒液に含有せしめることにより、存在のプロテアーゼは先ずこの含有のプロテインを分解して失活、消失して、ウイルス感染を困難にするという利点がある。プロテインの種類は特に選ばず10~20ppmの微量で充分でこの濃度は口腔用殺菌消毒液の殺菌効果には全く影響しない。
また、本発明でいうウイルスとは、インフルエンザウイルス、ライノウイルス、コロナウイルス、アデノウイルス、RSウイルス、鳥インフルエンザウイルス、ノロウイルス、肝炎ウイルス、エイズウイルス、ロタウイルス等を例示することができる。
また、非ヒト動物においても、本発明の口腔内殺菌消毒液を口腔に含ませたり、鼻腔内の殺菌消毒することで、前記病原体の感染を予防することが可能である。
口腔内や鼻腔内の消毒手法としては、常法に従えばよいが、例えば、うがい、ゆすぎの他、口腔内殺菌消毒液をスプレーしたり、口腔内殺菌消毒液を含ませた綿棒等で口腔又は鼻腔の表面に接触させればよい。
なお、非ヒト動物としては、ネコ、イヌ、ウサギ、ニワトリ、ヒツジ、ヤギ、ブタ、ウシ、ウマ等の家畜が挙げられる。
<溶液α>:塩化第二鉄・六水和物0.96gを水200mlに溶解する。
<溶液β>:水800mlにアルギン酸ナトリウム8gを添加、加湿溶解する。
該液にL-システイン1g、L-アスコルビン酸0.1g、ソルビン酸カリウム0.05g、ラウリル硫酸ナトリウム0.1g、ミョーバン(硫酸アルミニウムカリウム)8g、L-メントール0.2g、シアル酸5mg、蛋白粉末(大豆由来)10mgを添加して溶解する。
以下同様の方法で本発明の口腔用殺菌消毒液(本うがい水と略す)を製造し製造例を2~8として表9-1、表9-2にまとめた。
うがいをした時、その効果の概略を唾液中に存在する生菌数の消長で見る事にした。製造例1及び2、その比較としての水のみでのうがい、汎用されるヨード系うがい薬、万能消毒液Aについてもテストした。夫々の試験区各3名、1回20秒うがいを3回行いその直後、30分後、1時間後、以降1時間毎に唾液を0.5ml採取、唾液1ml中に存在する生菌数を常法に従い計測した。結果を表10に示す。表中の数値は夫々3名の平均値の概算を記載したものである。尚、括弧内はうがい前の菌数を100とした場合の菌数の割合を示す。測定時間中は正確を期する為に飲食物を一切口にする事は禁じた。
対してうがい薬として推奨されるポピドンヨードの場合、直後2%まで減少するがその後は徐々に増加、1時間後には30%のレベルに、5時間後には元に戻った。万能消毒液を使用した時は直後2%、1時間後にも15%の水準を保っていたが8時間を経て元の菌数になった。
これらに対して本うがい水を採用した場合は15分後まで菌は検出されず30分後に初めて出現、1時後経過でも3~5%その後も同じレベルをしばらく維持、6時間後から徐々に増え始め、8時間後に20%前後(万能殺菌消毒液の1~1.5時間経過と同レベル)、元の菌数に復活するには12時間以上を要した。
唾液中の菌数と粘膜上の菌数とは異なるとは言え、本うがい水の効果は少なくとも8時間は保持できるといえる。したがって、本うがい水を用いて、例えば、一日あたり、朝、昼、晩の3回、うがいを行うことで、経口や上気道からの感染を起す病原体に対して、きわめて有効な感染予防効果が得られると推測される。
次に製造例3で作成したうがい水でうがいをした時、被験者3名の粘膜上に存在する生菌数の推移を調査した。粘膜には唾液も付着し、試験例1に準じた結果になるのではとの推測の元、唾液の影響を受けにくい上部の歯肉部から採取場所を変えながら経時的に1辺5mmの滅菌ガーゼで拭い、常法(ワプス法)に従い計測した。その結果を表11に示す。
尚、うがい前の菌数を100として表した。また、♂は男性、♀は女性を示す。
口唇は粘膜ではないが、唾液の影響は殆ど受けない為、口唇に製造例5で作製した本うがい水を塗布、口唇上の菌の消長を検査した。
塗布前の上唇左半分に付着の菌数を測定、塗布し、4時間後に上唇右半分、8時間後下唇左半分、12時間後下唇右半分に付着している菌数をワプス法にて測定した。その間食事はゼリー状の栄養食(大塚製薬(株)製、「エネルゲン」(登録商標))をストローにて吸い込むに止め、極力外部から受ける影響を排除した。
結果を表12に示す。
自他共に口臭に悩んでいる10名に対して各種製造法で作製したうがい水で1回20秒3回(計1分間)2回/日1週間口うがいを行った。食事は臭いの強い食物(にんにく、にら等)を除いては自由摂食とした。
無臭性の高いポリエステル素材からなる匂い袋(2L)に毎朝起床時(歯磨き前)に息を吹き込み、シリコン詮にて密封、臭いに敏感なモニター3名によって口臭の増減と性質の官能テストを行った。その結果の一部を表13に示した。
尚、臭い感覚の強さは6段階法によって表示
0・・・無臭
1・・・やっと僅かに臭いが感じられる
2・・・楽に感じる臭い(臭いの性質が想像しうる)
3・・・明らかに感じる臭い
4・・・強い臭い
5・・・耐えられない程強く感じる臭い
0・・・快でも不快でもない
-1・・・やや不快
-2・・・不快
-3・・・非常に不快
-4・・・極端に不快
臭いの性質を表現する不快さはより急減するか又は消失し、まだ臭いが少々感じられる人でも不快さは全くなくなった。
(1)歯周病が進行し、治療に難渋する8名(何れも歯周ポケットが深い)に対して製造例3で作製した本うがい水で毎日2回口腔内だけのうがいを2ヶ月間継続して行った。
何れも歯周病原性の高いPoryphyromonas gingivalis、Prevotella intermedia及びActinobacillus actinomycetemcomitansが多数存在し程度の差はあれ歯肉が腫れて口臭が強く歯のぐらつきが見られた。
代表例の3名の治療成績について表14に記載した。
歯周ポケットの開口部はさほど変わりはないものの歯肉が盛り上がり色調も2ヵ月後にはピンク~赤色に戻り強い口臭も全員消失した。
K.T氏に於いては歯のぐらつきもなくなり、固いピーナッツなどもかめる迄になった。
このまま継続してうがいを行えば幾人かは特別な治療をせずとも完全治癒に到るのではとの希望を抱かせるに充分な治療成績であった。
尚、虫歯が深いC3のケースでは若干色調が薄くなる程度で症状には変わりがなかった。
慢性副鼻腔炎に羅患している5名に対して製造例6で作製したうがい水で、毎日1回鼻洗浄(鼻うがい)を3ヶ月間行った。自覚症状並びに病理学的所見により診断した結果5人全員2週間を過ぎた頃から症状の軽減が見られ、2ヵ月後には病理学的検査でもレントゲン検査でもそれが確認された。4ヵ月後には5名中3名が完治したとの報告を受けた。
口内炎やのどの炎症で腫脹や痛みのある3名に製造例2のうがい水で2回/日うがいを行った。
何れも1~2日後長くとも3日後にはこれら不快な症状は消滅した。これは汎用される消炎酵素剤を服用したケースと類似の治療成績であった。
SPF有精卵で培養したH1N1型のインフルエンザウイルス液の1mlを1000mlの水で希釈した。
製造例4で作製したうがい水でうがいをした直後と、1時間後、以降1時間毎に有志の人7名に該ウイルス希釈液を喉内に1~1.5秒スプレーにて噴霧したが、何れもインフルエンザに羅患しなかった。
心疾患や糖尿病などいわゆる生活習慣病を除けば病気の中で占める感染症の割合は大きく、その病原体の大半は気道や口から侵入する事により感染が成立する。それを未然に防ぐには感染症に対する正しい知識、衛生的な環境や日常の手洗いとうがいの励行が基本線である事は間違いのない所であろう。
手洗いは別としても従来のうがいはその場限りであり、またそうかと言って過度のうがいは喉に障害を与え感染を助長するだけである。
本発明のうがい水はこれ等の欠点を一掃し利便性豊かに改良したもので、感染症が地球上から絶滅しない限り用途は無限であろう。
一例を上げれば公衆衛生先進国の日本に於いてさえインフルエンザに毎年1000万人が感染し2009年は豚由来の新型インフルエンザが年少者を中心に猛威を振るっている。さらには時間の問題とも言われる高病原性の鳥インフルエンザウイルス(H1N5型)の変異によるパンデミック(世界的大流行:死者は推定1億人)の防衛と封じ込めにも本うがい水によるうがいは簡便かつ廉価に行えるという点からもその利用価値は高い。
Claims (16)
- 抗菌作用を有する金属イオン、L-システイン、L-アスコルビン酸、非イオン系を除く界面活性剤、増粘剤及び収斂剤を含有することを特徴とする口腔用殺菌消毒液。
- 抗菌作用を有する金属イオンがIII価の鉄イオン(Fe3+)、II価の鉄イオン(Fe2+)、亜鉛イオン(Zn2+)、銅イオン(Cu2+)、コバルトイオン(Co2+)、ニッケルイオン(Ni2+)及び銀イオン(Ag+)からなる群より選ばれる1種又は2種以上である請求項1に記載の口腔用殺菌消毒液。
- 抗菌作用を有する金属イオンの濃度が、III価の鉄イオンでは50~200ppm、II価の鉄イオンでは110~400ppm、亜鉛イオンでは7.5~125ppm、銅イオンでは15~60ppm、コバルトイオンでは180~300ppm、ニッケルイオンでは85~175ppm、及び銀イオンでは1~3ppmである請求項2に記載の口腔用殺菌消毒液。
- L-システインの濃度が100~1000ppm及びL-アスコルビン酸の濃度が100~500ppmである請求項1~3のいずれかに記載の口腔用殺菌消毒液。
- 非イオン系を除く界面活性剤が、アルキルベンゼンスルホン酸塩、直鎖アルキルベンゼンスルホン酸塩、ポリオキシエチレンアルキルエーテル硫酸塩、高級アルコール硫酸エステル塩、ラウリル硫酸ナトリウム、ラウロイルサルコシンナトリウム、塩化ステアリルジメチルベンゼンアンモニウム、塩化ベンザルコニウム、塩化ベンゼントニウム、塩化アルキルジアミノエチルグリシン及び塩酸アルキルポリアミノエチルグリシンからなる群より選ばれる1種又は2種以上である請求項1~4のいずれかに記載の口腔用殺菌消毒液。
- 非イオン系を除く界面活性剤の濃度が20~100ppmである請求項1~5のいずれかに記載の口腔用殺菌消毒液。
- 増粘剤がコーンスターチ、寒天、アルギン酸ナトリウム、コンドロイチン硫酸塩及びヒアルロン酸からなる群より選ばれる1種又は2種以上である請求項1~6のいずれかに記載の口腔用殺菌消毒液。
- 増粘剤の濃度が単独添加の場合にはコーンスターチでは20000~35000ppm、寒天では1000~1500ppm、アルギン酸ナトリウムでは5000~8000ppm、コンドロイチン硫酸塩では8000~15000ppm、ヒアルロン酸では3000~5000ppmである請求項7に記載の口腔用殺菌消毒液。
- 収斂剤がミョウバン類、カテキン類、にがり類又はホップエキスである請求項1~8のいずれかに記載の口腔用殺菌消毒液。
- 収斂剤の濃度がミョウバン類では8000~12000ppm、カテキン類では5000~10000ppm、にがり類では8000~20000ppm、ホップエキスでは10000~15000ppmである請求項9に記載の口腔用殺菌消毒液。
- ソルビン酸、ソルビン酸塩、安息香酸、安息香酸塩及びパラオキシ安息香酸エステルからなる群より選ばれる1種又は2種以上をさらに含む請求項1~10のいずれかに記載の口腔用殺菌消毒液。
- ソルビン酸、ソルビン酸塩、安息香酸、安息香酸塩及びパラオキシン安息香酸エステルの濃度の総量が50~100ppmである請求項11に記載の口腔用殺菌消毒液。
- シアル酸5~10ppm、プロテイン10~20ppm及びハーブエキス又は精油100~200ppmからなる群より選ばれる1種又は2種以上をさらに含む請求項1~12のいずれかに記載の口腔用殺菌消毒液。
- ハーブエキス又は精油がユーカリ、ミント、カモミール、ラベンダー、オレガノ、グローブ、ローズマリー、タイム、ネロリ、パイン、ベルガモット、シダーウッド、ヒノキチオール、及びティートリーオイルからなる群より選ばれる1種又は2種以上である請求項13記載の口腔用殺菌消毒液。
- pHが2.5乃至4.0の範囲内に調整された請求項1~14のいずれかに記載の口腔用殺菌消毒液。
- オストワルド相対粘度計による測定で、水道水の粘度を1とした場合の相対粘度が1.5~2.2である請求項1~15のいずれかに記載の口腔用殺菌消毒液。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2010/051203 WO2011092835A1 (ja) | 2010-01-29 | 2010-01-29 | 持続性口腔用殺菌消毒液 |
JP2011551632A JP5673560B2 (ja) | 2010-01-29 | 2010-01-29 | 持続性口腔用殺菌消毒液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2010/051203 WO2011092835A1 (ja) | 2010-01-29 | 2010-01-29 | 持続性口腔用殺菌消毒液 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011092835A1 true WO2011092835A1 (ja) | 2011-08-04 |
Family
ID=44318843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/051203 WO2011092835A1 (ja) | 2010-01-29 | 2010-01-29 | 持続性口腔用殺菌消毒液 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5673560B2 (ja) |
WO (1) | WO2011092835A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014198700A (ja) * | 2013-03-29 | 2014-10-23 | 株式会社ピカソ美化学研究所 | 防腐剤および外用組成物、ならびに着色低減方法 |
KR20150136540A (ko) * | 2013-04-02 | 2015-12-07 | 베링거 인겔하임 인터내셔날 게엠베하 | 인후통, 쉰목소리 및 관련 마른 기침 치료용, 및 구강 및 인두강의 염증성 질환 치료용 로젠지제 |
JP2016507534A (ja) * | 2013-02-07 | 2016-03-10 | ゴンザレス トマス ベルナルド ガルヴァン | 口腔粘膜炎を治療するための口腔殺菌性組成物 |
JP2018184362A (ja) * | 2017-04-25 | 2018-11-22 | 株式会社R−good | 殺菌性組成物 |
EP3389594A4 (en) * | 2015-12-18 | 2019-05-29 | Colgate-Palmolive Company | STRUCTURING SODIUM AND ZINC ALGINATE AND METHODS OF MAKING AND USING SAME |
CN111067102A (zh) * | 2019-12-30 | 2020-04-28 | 嘉必优生物技术(武汉)股份有限公司 | 一种提高n-乙酰神经氨酸水溶液稳定性的方法 |
US20220133858A1 (en) * | 2020-10-29 | 2022-05-05 | Rama D. Jager | Pharmacological compositions for the treatment and prevention of coronavirus disease |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4405599A (en) * | 1982-07-06 | 1983-09-20 | Smigel Irwin E | Toothpaste for natural teeth as well as composite filling material |
JPS6013707A (ja) * | 1983-07-05 | 1985-01-24 | Kaoru Ohashi | 歯みがき剤 |
JPS62138420A (ja) * | 1985-12-11 | 1987-06-22 | Sato Seiyaku Kk | 口腔用組成物 |
JPS63211219A (ja) * | 1987-02-27 | 1988-09-02 | Taiyo Koryo Kk | う蝕予防剤 |
JPH03101623A (ja) * | 1989-09-14 | 1991-04-26 | Mitsui Norin Kk | インフルエンザウィルス感染予防剤 |
JPH05944A (ja) * | 1991-06-21 | 1993-01-08 | Taiyo Kagaku Co Ltd | 歯周病原因菌付着阻害用組成物 |
JP2000109428A (ja) * | 1998-10-05 | 2000-04-18 | Taisho Pharmaceut Co Ltd | 咽頭粘膜用組成物 |
CN1252993A (zh) * | 1998-10-30 | 2000-05-17 | 邢万章 | 治疗口腔疾病的含漱愈液 |
JP2004300043A (ja) * | 2003-03-31 | 2004-10-28 | Rikio Sato | にがりを配合した薬剤 |
JP2007070365A (ja) * | 2006-12-04 | 2007-03-22 | Kao Corp | 口腔細菌の共凝集抑制剤 |
JP2009149537A (ja) * | 2007-12-19 | 2009-07-09 | Lion Corp | 口腔用組成物 |
WO2009133616A1 (ja) * | 2008-05-01 | 2009-11-05 | アンスラックス スポアーズ キラー コーポレーション リミテッド | 万能殺菌消毒液 |
-
2010
- 2010-01-29 WO PCT/JP2010/051203 patent/WO2011092835A1/ja active Application Filing
- 2010-01-29 JP JP2011551632A patent/JP5673560B2/ja not_active Expired - Fee Related
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4405599A (en) * | 1982-07-06 | 1983-09-20 | Smigel Irwin E | Toothpaste for natural teeth as well as composite filling material |
JPS6013707A (ja) * | 1983-07-05 | 1985-01-24 | Kaoru Ohashi | 歯みがき剤 |
JPS62138420A (ja) * | 1985-12-11 | 1987-06-22 | Sato Seiyaku Kk | 口腔用組成物 |
JPS63211219A (ja) * | 1987-02-27 | 1988-09-02 | Taiyo Koryo Kk | う蝕予防剤 |
JPH03101623A (ja) * | 1989-09-14 | 1991-04-26 | Mitsui Norin Kk | インフルエンザウィルス感染予防剤 |
JPH05944A (ja) * | 1991-06-21 | 1993-01-08 | Taiyo Kagaku Co Ltd | 歯周病原因菌付着阻害用組成物 |
JP2000109428A (ja) * | 1998-10-05 | 2000-04-18 | Taisho Pharmaceut Co Ltd | 咽頭粘膜用組成物 |
CN1252993A (zh) * | 1998-10-30 | 2000-05-17 | 邢万章 | 治疗口腔疾病的含漱愈液 |
JP2004300043A (ja) * | 2003-03-31 | 2004-10-28 | Rikio Sato | にがりを配合した薬剤 |
JP2007070365A (ja) * | 2006-12-04 | 2007-03-22 | Kao Corp | 口腔細菌の共凝集抑制剤 |
JP2009149537A (ja) * | 2007-12-19 | 2009-07-09 | Lion Corp | 口腔用組成物 |
WO2009133616A1 (ja) * | 2008-05-01 | 2009-11-05 | アンスラックス スポアーズ キラー コーポレーション リミテッド | 万能殺菌消毒液 |
Non-Patent Citations (4)
Title |
---|
DATABASE MEDLINE U.S. NATIONAL LIBRARY OF MEDICINE(NLM); PUTT, M.S. ET AL: "Evaluation of an alum- containing mouthrinse in children for plaque and gingivitis inhibition during 4 weeks of supervised use", accession no. STN Database accession no. 1996265346 * |
MIYAKO HIRAI ET AL.: "Nigari Mizu o Mochiita Koku Care no Kokoromi-Isodine Gargle Eki tono Hikaku", JOURNAL OF IWAMIZAWA MUNICIPAL GENERAL HOSPITAL, vol. 31, no. 1, 2005, pages 51 * |
PUTT, M.S. ET AL.: "Evaluation of an alum- containing mouthrinse in children for plaque and gingivitis inhibition during 4 weeks of supervised use", PEDIATRIC DENTISTRY, vol. 18, no. 2, 1996, pages 139 - 144 * |
TAKEO MITSUI ET AL., SHIN KESHOHIN GAKU, 2001, pages 532 - 534 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016507534A (ja) * | 2013-02-07 | 2016-03-10 | ゴンザレス トマス ベルナルド ガルヴァン | 口腔粘膜炎を治療するための口腔殺菌性組成物 |
JP2014198700A (ja) * | 2013-03-29 | 2014-10-23 | 株式会社ピカソ美化学研究所 | 防腐剤および外用組成物、ならびに着色低減方法 |
KR20150136540A (ko) * | 2013-04-02 | 2015-12-07 | 베링거 인겔하임 인터내셔날 게엠베하 | 인후통, 쉰목소리 및 관련 마른 기침 치료용, 및 구강 및 인두강의 염증성 질환 치료용 로젠지제 |
JP2016515594A (ja) * | 2013-04-02 | 2016-05-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 咽喉炎、嗄声及び関連の空咳、並びに口腔及び咽頭腔の炎症性疾患の治療用ロゼンジ剤 |
KR102218148B1 (ko) * | 2013-04-02 | 2021-02-23 | 사노피-아벤티스 도이칠란트 게엠베하 | 인후통, 쉰목소리 및 관련 마른 기침 치료용, 및 구강 및 인두강의 염증성 질환 치료용 로젠지제 |
EP3389594A4 (en) * | 2015-12-18 | 2019-05-29 | Colgate-Palmolive Company | STRUCTURING SODIUM AND ZINC ALGINATE AND METHODS OF MAKING AND USING SAME |
US10555880B2 (en) | 2015-12-18 | 2020-02-11 | Colgate-Palmolive Company | Sodium zinc alginate structurant and methods for making and using the same |
JP2018184362A (ja) * | 2017-04-25 | 2018-11-22 | 株式会社R−good | 殺菌性組成物 |
CN111067102A (zh) * | 2019-12-30 | 2020-04-28 | 嘉必优生物技术(武汉)股份有限公司 | 一种提高n-乙酰神经氨酸水溶液稳定性的方法 |
CN111067102B (zh) * | 2019-12-30 | 2023-08-08 | 嘉必优生物技术(武汉)股份有限公司 | 一种提高n-乙酰神经氨酸水溶液稳定性的方法 |
US20220133858A1 (en) * | 2020-10-29 | 2022-05-05 | Rama D. Jager | Pharmacological compositions for the treatment and prevention of coronavirus disease |
Also Published As
Publication number | Publication date |
---|---|
JPWO2011092835A1 (ja) | 2013-05-30 |
JP5673560B2 (ja) | 2015-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5673560B2 (ja) | 持続性口腔用殺菌消毒液 | |
Mathur et al. | Chlorhexidine: The gold standard in chemical plaque control | |
US10195239B2 (en) | Extract of Trigonella foenum-graecum | |
US20110236504A1 (en) | Versatile disinfectant | |
CA2599543A1 (en) | Oral health care drink and method for reducing malodors | |
CN108042420B (zh) | 一种用于口腔保健的组合物及其应用 | |
JP5434915B2 (ja) | ヘリコバクターピロリ菌の駆除剤 | |
CN109010098A (zh) | 抗菌漱口液及其制备方法 | |
RU2601905C1 (ru) | Способ лечения гингивита | |
SAMbAwA et al. | Comparison of antibacterial efficacy chlorohexidine gluconate and saudi myrrh mouthwashes in the oral cavity | |
KR102251911B1 (ko) | 은 이온 항균 손세정제 및 그 제조 방법 | |
CN107485584A (zh) | 一种口腔护理组合物 | |
CN107242983A (zh) | 一种含艾叶黄酮的漱口水及其制备方法 | |
CN109512683B (zh) | 一种聚维酮碘组合物及其制备方法与应用 | |
RU2691410C1 (ru) | Средство для ухода за полостью рта и горла | |
RU2283100C1 (ru) | Способ лечения пародонтита | |
RU2789465C1 (ru) | Способ профилактики и лечения патологических изменений зубочелюстной системы при пародонтозе | |
WO2022130732A1 (ja) | 海藻類及びその抽出物による口腔用、鼻孔用又は咽喉用の衛生用品 | |
Kiyomiddin et al. | MEDICINAL PROPERTIES OF PROPOLIS AND ITS USE IN DENTAL DISEASES | |
Karthikeyan | A Comparative evaluation of antibacterial efficacy of neem and turmeric with and without addition of calcium hydroxide against enterococcus faecalis: An In Vitro study | |
DHANKER et al. | Fluoride alternatives in the prevention of dental caries: A Review | |
Anitha Rao et al. | In vitro antimicrobial efficacy of photoactivated cow urine against enterococcus faecalis | |
CA3191294A1 (en) | Iodine and polyol composition, method, and use | |
JP2022094911A (ja) | 海藻類及びその抽出物による口腔用、鼻孔用又は咽喉用の衛生用品 | |
JP2022163808A (ja) | 口腔菌叢改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10844596 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011551632 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 09/11/2012) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10844596 Country of ref document: EP Kind code of ref document: A1 |